Dr. Lal PathLabs to acquire 70% of SN Genelab for up to INR 168 Crores plus earn-out
As filed · Dr. Lal Path Labs Ltd. has informed the Exchange about acquisition of 70% stake in SN Genelab Private Limited ( S N Gene ) from its existing Shareholders. Post acquisition, S N Gene shall become a Sub
What happened
FactDr. Lal PathLabs approved the acquisition of a 70% stake in SN Genelab Private Limited, a genomics diagnostics company. The transaction is expected to close by November 30, 2026, after which SN Genelab will become a subsidiary.
Why it matters
CapitSignal interpretationAn acquisition spends cash or issues shares today for earnings that arrive later, so the price paid and the funding route decide whether holders gain.
Scale
- 6.3% of FY26 revenue
₹168 Cr stated in the filing against ₹2,647.6 Cr revenue (FY26, standalone)
Source: financial_facts · exchange_table
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
RevisedNormally our maintenance CAPEX is about Rs. 60 – Rs. 70 crore a year.
Secondly would be around some of the high-end radiology centers that we are slowly rolling out, whether it is in Delhi NCR and other Tier 2 markets in North, that is also a bit of capex that we put in besides our maintenance annual capex that we do.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Consideration and how it is funded
- Revenue and profit of the target
- Expected completion date
- next year I think we should be better than that, maybe between 11% - 12%. (management committed by FY26)
- we believe that we should be able to recover quickly in the next 1-2 quarters. (management committed by H1 FY26)
Evidence
- Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on September 24, 2026.(opens the original filing in a new tab)
- Earlier statement · Q4 FY25
- Latest statement · Q1 FY27
- Earlier statement · Q4 FY25
How CapitSignal classified this
- Reasoning:
- The acquisition adds genomics diagnostic capabilities and advanced diagnostic services to Dr. Lal PathLabs' portfolio. SN Genelab's turnover increased from 43.27 Crores in FY 2024 to 57.96 Crores in FY 2026.
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%